Technology
Moderna has launched a clinical trial for its mRNA-based Ebola vaccine, marking a significant step in combating this viral disease.
Technology
Ramy Farid of Schrödinger reflects on the evolving role of AI in biotech, envisioning clearer perceptions in the industry within five years.
Technology
A recent Medicare pilot proposal risks reducing savings for retail drugs. Meanwhile, merger talks between AstraZeneca and Bristol Myers Squibb have been denied.
Technology
A new Medicaid toolkit emphasizes stricter oversight and measurable outcomes for autism therapies, raising concerns around ABA services and telehealth.
Technology
Excluding rare disease therapies from Medicare's drug pricing pilots could significantly reduce overall savings, according to recent research.
Technology
Despite high diagnosis rates, many U.S. men miss out on MRI screenings for prostate cancer, which could lead to better outcomes.
Technology
Novo Nordisk's ziltivekimab, aimed at targeting inflammation, showed no reduction in cardiovascular events despite lowering inflammation markers.
Technology
The American Diabetes Association, once praised for its bravery, now faces criticism for its handling of dissent within the medical community.
Technology
As advancements accelerate in rare disease therapies, LGMD patients face urgency, with time impacting their muscle function and access to new treatments.
Sports
Recent critiques of a Covid study misrepresent key findings and overlook significant challenges in assessing nonpharmaceutical interventions' impacts.
Technology
In San Diego, a surge in syphilis cases highlights the challenges researchers face amid a drug shortage and complex patient interactions.
Technology
Capricor Therapeutics faces skepticism over its Duchenne MD therapy data, while the biotech sector grapples with leadership turmoil and FDA scrutiny.
Technology
Increased oil prices may significantly hike the cost of certain medicines, highlighting the need to reduce reliance on petrochemicals for production.
Technology
A recent FDA panel's critical vote against a Duchenne drug highlights ongoing scrutiny of digital health practices, particularly Hims & Hers.
Technology
Latigo Biotherapeutics' LTG-001 demonstrates significant pain relief in Phase 2 trials, marking a potential shift in non-opioid pain management options.